November 19, 2025 - Non-regulatory SynAct Participating at Redeye Autoimmune and Inflammatory Diseases event on November 19th
November 3, 2025 - Non-regulatory Resomelagon Phase-2B ADVANCE Study Update: 190 Patients Randomized Tracking for Year-End Recruitment Completion
October 31, 2025 - Non-regulatory SynAct Pharma Participating in Partnering and Investor Conference Bio-Europe® 2025
October 28, 2025 - Non-regulatory Edison Investment Research Ltd. Initiates Coverage of SynAct Pharma
September 29, 2025 - Regulatory Proposal for a resolution on authorization for the Board of Directors to resolve on acquisition and transfer of own shares
September 8, 2025 - Non-regulatory SynAct Pharma AB – Notification of Warrant and Share Transactions by Hunter Capital AB and Heights Capital Management
July 15, 2025 - Regulatory Correction: SynAct to receive SEK 17.7 million after conversion of warrants
June 26, 2025 - Non-regulatory A majority of SynAct Pharma’s Board and management have acquired shares with a value of more than SEK 1 million
June 4, 2025 - Non-regulatory SynAct Pharma Refines Development Strategy for Lead Compound Resomelagon (AP1189)
June 4, 2025 - Regulatory SynAct Pharma AB carries out a directed share issue of SEK 37 million and extends its financial runway to end of 2026
June 3, 2025 - Regulatory SynAct Pharma takes out a credit facility of SEK 30 million that extends the company’s financial runway to mid-2026, which strongly strengthens partnership opportunities.
May 12, 2025 - Non-regulatory SynAct receives Issue Notification and Patent Term Adjustment for US patent covering resomelagon (AP1189) combination therapy
April 23, 2025 - Non-regulatory SynAct receives Notice of Allowance for grant of US Patent covering resomelagon (AP1189) combination therapy
April 16, 2025 - Non-regulatory SynAct Pharma to participate at BIO International Convention in Boston June 16-19
April 11, 2025 - Non-regulatory SynAct Pharma Announces Initiation of Phase II Study with resomelagon (AP1189) for the Treatment of Patients with Dengue
March 17, 2025 - Non-regulatory The European Patent Office issues an Intention to Grant a European Patent Covering the Clinical Formulation of Resomelagon (AP1189)
March 4, 2025 - Non-regulatory Pivotal US Patent Protecting Resomelagon (AP1189) Granted to SynAct Pharma
February 20, 2025 - Regulatory SynAct’s Nomination Committee proposes Jeppe Ragnar Andersen to the Board
December 17, 2024 - Regulatory SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm
December 17, 2024 - Non-regulatory SynAct Pharma to join J.P. Morgan Healthcare Conference in San Francisco
November 27, 2024 - Non-regulatory SynAct Pharma receives EU trial approval for the Phase 2b ADVANCE study with resomelagon (AP1189)
November 20, 2024 - Regulatory SynAct Pharma intends to carry out directed issues totalling approximately 45 MSEK and a fully guaranteed rights issue totalling approximately 20 MSEK
November 14, 2024 - Non-regulatory SynAct Pharma presents positive clinical data on resomelagon (AP1189) supporting development for the treatment of RA at ACR Convergence
September 23, 2024 - Non-regulatory SynAct initiates the Phase 2b ADVANCE study with resomelagon (AP1189) in the US
September 13, 2024 - Non-regulatory SynAct Pharma to present clinical data on resomelagon (AP1189) at ACR Convergence
August 30, 2024 - Non-regulatory First scientific publication showing treatment potential of a pro-resolving compound in human virus infection
July 1, 2024 - Non-regulatory SynAct initiates filing process for Phase 2b ADVANCE study with resomelagon
April 23, 2024 - Regulatory Changes in SynAct Pharma’s Nomination Committee ahead of the 2024 Annual General Meeting
March 27, 2024 - Regulatory SynAct Pharma AB has successfully completed the bookbuilding procedure – directed issues provide the company with a total of up to 49.2 MSEK.
March 26, 2024 - Regulatory SynAct Pharma AB announces intention to carry out directed share issues in total of approximately 48 MSEK
March 25, 2024 - Regulatory SynAct Pharma AB (publ) (“SynAct”) brings forward the publication of the annual report.
March 10, 2024 - Regulatory SynAct Pharma announces outcomes of the independent audit of the 4-week RESOLVE P2a clinical trial in Rheumatoid Arthritis
February 23, 2024 - Regulatory SynAct Pharma AB (publ) (“SynAct”) today publishes the fourth quarter and annual results of 2023.
February 22, 2024 - Non-regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial supporting continued development of the compound in rheumatoid arthritis
January 30, 2024 - Non-regulatory SynAct Pharma expands its Rheumatology Clinical Advisory Board with three new highly experienced advisors
January 28, 2024 - Regulatory The Board of Directors of SynAct Pharma AB has received a request to convene an EGM
November 1, 2023 - Regulatory SynAct Pharma announces evaluation of the 4-week RESOLVE P2a clinical trial in moderate to severely active rheumatoid arthritis patients with an incomplete response to methotrexate
October 12, 2023 - Regulatory SynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm
October 11, 2023 - Regulatory SynAct Pharma AB carries out a directed issue of shares and warrants raising initial gross proceeds of SEK 60.5 million
October 3, 2023 - Non-regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial further supporting efficacy and activity seen in patients with elevated CRP
September 12, 2023 - Regulatory SynAct Pharma announces additional data from the EXPAND P2b clinical trial and identifies population with responsiveness to resomelagon
September 4, 2023 - Regulatory SynAct Pharma announces top line data from the 12-week EXPAND P2b clinical trial in severely active newly diagnosed rheumatoid arthritis patients
August 17, 2023 - Non-regulatory SynAct Pharma completes dosing in part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)
July 20, 2023 - Non-regulatory SynAct Pharma completes patient recruitment for part A of combined Phase 2a/b RESOLVE study of resomelagon (AP1189) in rheumatoid arthritis (RA)
July 14, 2023 - Non-regulatory SynAct Pharma announces the completion of dosing in the Phase 2b EXPAND study of resomelagon (AP1189) in early severe rheumatoid arthritis patients
June 29, 2023 - Non-regulatory SynAct Pharma to present at 19th World Congress of Basic and Clinical Pharmacology in Glasgow on July 4
May 25, 2023 - Regulatory Bulletin from the annual general meeting in SynAct Pharma AB on May 25, 2023
April 24, 2023 - Regulatory SynAct Pharma completes patient recruitment for Phase 2b EXPAND study of AP1189 in early severe Rheumatoid Arthritis
April 17, 2023 - Non-regulatory SynAct Pharma announces program for the upcoming Capital Markets Day in Stockholm on May 5, 2023
April 3, 2023 - Regulatory The Nomination Committee of SynAct Pharma proposes Uli Hacksell as new Chairman and Thomas von Koch as new Board member
March 28, 2023 - Non-regulatory SynAct Pharma to host a Capital Markets Day in Stockholm on May 5, 2023
February 1, 2023 - Regulatory Patrik Renblad is leaving SynAct Pharma and the search for a new CFO has been initiated
December 16, 2022 - Non-regulatory SynAct Pharma initiates dosing in the RESOLVE study in DMARD-IR RA
December 12, 2022 - Regulatory SynAct Pharma to make strategic acquisition of Swiss biotech company TXP Pharma
December 12, 2022 - Regulatory SynAct Pharma carries out a directed share issue of SEK 80 million in connection with the acquisition of TXP Pharma
November 1, 2022 - Non-regulatory SynAct Pharma receives IND clearance from the FDA for Phase 2a/b trial of AP1189 in RA
September 27, 2022 - Non-regulatory SynAct Pharma enrolls first patient in Phase 2b trial of AP1189 in RA
August 16, 2022 - Non-regulatory Resomelagon proposed international nonproprietary name (INN) for AP1189
July 21, 2022 - Non-regulatory SynAct Pharma improves the design of the ongoing Phase 2a study in iMN
May 20, 2022 - Regulatory Bulletin from the annual general meeting in SynAct Pharma AB on May 20, 2022
May 12, 2022 - Regulatory Last day of trading in paid subscribed shares (Sw. betalda tecknade aktier) in SynAct Pharma AB
April 1, 2022 - Non-regulatory SynAct publishes prospectus in connection with a fully guaranteed rights issue
March 28, 2022 - Regulatory Bulletin from the extraordinary general meeting on March 28, 2022, in SynAct Pharma AB
March 28, 2022 - Regulatory SynAct resolves on a fully guaranteed rights issue of approximately SEK 150 million
March 9, 2022 - Regulatory The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB
December 1, 2021 - Non-regulatory SynAct Pharma strengthens its patent portfolio for AP1189 following an Intention to Grant from the European Patent Office
November 30, 2021 - Regulatory SynAct Pharma’s AP1189 meets primary endpoint and demonstrates favorable safety profile in Rheumatoid Arthritis patients with active joint disease in the Phase 2a BEGIN study
November 19, 2021 - Non-regulatory SynAct Pharma announces Nomination Committee in respect of AGM 2022
November 11, 2021 - Non-regulatory SynAct Pharma takes advantage of new toxicology results and new tablet formulation to re-design and optimize the study programme with AP1189 in Nephrotic Syndrome
September 24, 2021 - Regulatory SynAct Pharma completes patient recruitment to the Phase 2a BEGIN study of AP1189 in early severe Rheumatoid Arthritis
August 27, 2021 - Regulatory SynAct Pharma: Interim Report January-June 2021 August 27, 2021 (Q2 2021 Report included)
August 27, 2021 - Regulatory SynAct Pharma Provides an Update on Patient Recruitment in the Phase 2a Clinical Trial of AP1189 in Rheumatoid Arthritis
August 25, 2021 - Regulatory SynAct strengthens IP portfolio – Grant of key European patent covering AP1189
August 20, 2021 - Regulatory SynAct Pharma to present new data on AP1189 for the treatment of rheumatoid arthritis at ACR Convergence 2021
July 7, 2021 - Regulatory SynAct Pharma Appoints Anders Dyhr Toft, MD, Ph.D., as Chief Medical Officer
July 7, 2021 - Regulatory SynAct Pharma AB Announces Additional Data from the Phase 2a Trial of AP1189 in Covid-19 Infected Patients and Reminds of Management Call to Discuss Results
July 2, 2021 - Regulatory SynAct Pharma Hosts Conference Call on Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients
June 30, 2021 - Regulatory SynAct Pharma AB Announces Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients
June 23, 2021 - Regulatory SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations
June 1, 2021 - Regulatory SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients
May 21, 2021 - Regulatory Bulletin from the annual general meeting in SynAct Pharma AB on 21 May 2021
May 14, 2021 - Regulatory SynAct Pharma AB: SynAct Pharma initiates collaboration on pharmacogenetic aspects of AP1189 compound in Rheumatoid arthritis with Barts and London School of Medicine, Queen Mary University of London.
May 12, 2021 - Regulatory SynAct Pharma partners with Örebro University to study cardiovascular disease
April 30, 2021 - Regulatory SynAct Pharma to participate at Kempen’s virtual Life Sciences Conference
April 13, 2021 - Regulatory SynAct strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 English version
March 18, 2021 - Regulatory SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version
March 1, 2021 - Regulatory SynAct Pharma’s CFO and board member sell shares to cover taxes on holdings
February 11, 2021 - Regulatory SynAct Pharma Names James Knight as Chief Business Officer – Already published in Swedish today
February 5, 2021 - Regulatory SynAct carries out a directed share issue and raises proceeds of SEK 80 million
February 4, 2021 - Regulatory SynAct explores the conditions for carrying out a directed share issue – English version – Published today 17.31 CET
February 4, 2021 - Regulatory SynAct Pharma prepares move to Nasdaq Stockholm – English version – Published today at 17.31 CET
January 11, 2021 - Regulatory Published in English – already published 11:18 CET today Disclosure notice in SynAct Pharma AB
November 9, 2020 - Regulatory SynAct Pharma Announces Positive Interim Phase 2 Data of AP1189 in Rheumatoid Arthritis
November 6, 2020 - Regulatory Bulletin from the extraordinary shareholders’ meeting in SynAct Pharma AB
October 20, 2020 - Regulatory Shareholders of SynAct Pharma proposes Uli Hacksell as new board member
October 12, 2020 - Regulatory English version of PR published 20201012 at 07.33AM SynAct Pharma completes part 1 of clinical phase II study with AP1189 in Rheumatoid Arthritis
September 23, 2020 - Regulatory Swedish version of press release published earlier today. SynAct Pharma initierar fas II-studie med AP1189 för behandling av ARDS i COVID-19-patienter
September 23, 2020 - Regulatory SynAct Pharma Initiates Phase II Study with AP1189 for the Treatment of ARDS in COVID-19 Patients
September 3, 2020 - Regulatory SynAct Pharma informs that the recruitment to part 1 in the Clinical Phase II study with AP1189 in Rheumatoid Arthritis is completed
September 1, 2020 - Regulatory SynAct Pharma Informs about Termination of Coverage Agreement with Redeye
August 28, 2020 - Regulatory SynAct Pharma Initiates RESOVIR: Scientific and clinical Collaboration to Explore AP1189 in Viral Infections
July 27, 2020 - Regulatory Synact Pharma announces outcome in the exercise of warrants, will receive approximately MSEK 32.4
July 15, 2020 - Regulatory SynAct Pharma AB: Update on SynAct Pharma´s Clinical Phase II study with AP1189 in Rheumatoid Arthritis
June 30, 2020 - Regulatory SynAct Pharma announces that the exercise period for warrants of the TO 2 series will start on July 1, 2020
June 29, 2020 - Regulatory SynAct Pharma has initiated the Phase II clinical study with AP1189 in Nephrotic Syndrome
June 25, 2020 - Regulatory SynAct Pharma’s Board of Directors and management sign subscription commitment for warrant exercise of series TO 2
June 2, 2020 - Regulatory SynAct Pharma´s clinical trial application for AP1189 in Nephrotic Syndrome approved by the Danish Medical Agency
May 25, 2020 - Regulatory SynAct Pharma files patent application for combination of AP1189 and Methotrexate for treatment of RA and other arthritic diseases
May 5, 2020 - Regulatory SynAct presents initial data from the first part of the Phase II study within RA and gives an update on its progression
March 31, 2020 - Regulatory SynAct Pharma submits clinical trial application for AP1189 in Nephrotic Syndrome
March 31, 2020 - Regulatory Translation – UK version of Swedish press release – published 08.00 AM. today – SynAct Pharma investigates the possibility of AP1189 as additional therapy in hospitalized patients with COVID-19
November 11, 2019 - Non-regulatory SynAct receives approval from the Swedish Medical Product Agency and the Swedish Ethical Review Authority regarding the clinical Phase IIa study with AP1189
October 21, 2019 - Regulatory SynAct conducts private placement and fully guaranteed rights issue with the aim of increasing the commercial value of AP1189
March 29, 2019 - Regulatory SynAct applies for start of phase IIa clinical study in patients with active arthritis
February 25, 2019 - Non-regulatory John Haurum and Terje Kalland are proposed as new members of the Board of Directors in SynAct Pharma AB
February 11, 2019 - Regulatory SynAct reported positive phase I results for candidate drug AP1189 and prepared funding for broadened phase II programmes
December 21, 2018 - Regulatory Dosing with candidate drug AP1189 in multiple-dose part of the Phase I study completed
December 10, 2018 - Regulatory SynAct’s candidate drug AP1189 exhibits continued favourable safety and plasma profiles in the multiple-dose part of the Phase I study
October 22, 2018 - Regulatory SynAct Pharma announced that AP1189 exhibits a favourable plasma profile in the Phase I study’s initial multiple-dose part
September 13, 2018 - Regulatory SynAct Pharma announced the start of the multiple-dose part of the Phase I study with AP1189
August 20, 2018 - Regulatory SynAct Pharma announced positive data from preclinical study in nephrotic syndrome with candidate drug AP1189
July 23, 2018 - Regulatory SynAct Pharma obtains regulatory approval for the implementation of the multiple-dose part in Phase I study with candidate drug AP1189
June 18, 2018 - Non-regulatory SynAct Pharma AB responds to questions about the further development of candidate drug AP1189
June 12, 2018 - Regulatory SynAct Pharma adapts the continued clinical development programme for AP1189 based on new results from the Phase I study
April 17, 2018 - Non-regulatory SynAct Pharma AB holds investor meetings in connection with the rights issue
April 10, 2018 - Regulatory Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)
April 6, 2018 - Non-regulatory Market announcement 86/18 – Information about the rights issue for SynAct Pharma AB
March 23, 2018 - Regulatory SynAct Pharma proposes a rights issue of SEK 22.4 million in order to increase the market potential for AP1189.
October 3, 2017 - Regulatory The first part of the clinical Phase I study with SynAct Pharma’s drug candidate AP1189 successfully completed
May 10, 2017 - Regulatory SynAct Pharma AB receives approval to start Clinical Phase I study with AP1189 – a new potential treatment for psoriatic arthritis
April 27, 2017 - Regulatory Utilisation of subscription options registered with Swedish Companies Registration Office
April 25, 2017 - Regulatory SynAct Pharma AB provides an update on the clinical development plan for AP1189
March 31, 2017 - Regulatory SynAct Pharma AB will raise 1,007,539.20 SEK through the utilisation of series TO 1 subscription options
March 9, 2017 - Regulatory SynAct Pharma AB retains subscription rights for series TO 1subscription option
March 9, 2017 - Regulatory The utilisation period of SynAct Pharma AB’s series TO 1 subscription options starts today
February 22, 2017 - Regulatory SynAct Pharma AB has received approval from the Ethics Committee and continues its dialogue with the French Medicines Agency
December 9, 2016 - Non-regulatory SynAct Pharma submits application for start of Phase I clinical study
October 28, 2016 - Non-regulatory SynAct Pharma fulfilled its commitments to the financier Seed Fund CapNova by a one-time payment
July 11, 2016 - Non-regulatory Trading starts in SynAct Pharma AB’s shares and subscription options on Aktietorget today
July 4, 2016 - Non-regulatory Market Announcement 174/16 – SynAct Pharma AB listed on Aktietorget 11 July 2016 – corrected version
May 30, 2016 - Non-regulatory Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)
May 24, 2016 - Non-regulatory Today the subscription period for SynAct Pharma AB’s issue opens, before the planned listing on Aktietorget
May 24, 2016 Publication of SynAct Pharma AB’s prospectus in connection with the issue ahead of planned listing on Aktietorget
May 9, 2016 - Non-regulatory Bulletin from the Extraordinary General Meeting of SynAct Pharma AB (publ)
